Gsa Capital Partners LLP Alector, Inc. Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$4.19 - $6.23 $126,211 - $187,660	-30,122 Reduced 47.37%	33,461 $152,000
Q1 2024 May 03, 2024	BUY	$5.69 - $8.08 $361,787 - $513,750	63,583 New	63,583 $382,000
Q3 2022 Nov 14, 2022	BUY	$8.19 - $13.2 $114,619 - $184,734	13,995 New	13,995 $132,000
Q2 2022 Aug 09, 2022	SELL	$7.65 - $14.24 $99,327 - $184,892	-12,984 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$13.02 - $20.78 $169,051 - $269,807	12,984 New	12,984 $185,000
Q4 2021 Feb 14, 2022	SELL	$19.35 - $25.54 $1 Million - $1.32 Million	-51,730 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$21.65 - $39.49 $534,819 - $975,521	24,703 Added 91.4%	51,730 $1.18 Million
Q2 2021 Aug 05, 2021	BUY	$15.5 - $22.48 $418,918 - $607,566	27,027 New	27,027 $563,000
Q4 2020 Feb 03, 2021	SELL	$9.4 - $16.7 $98,418 - $174,849	-10,470 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$10.54 - $24.96 $110,353 - $261,331	10,470 New	10,470 $110,000

168

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $159M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.